Tag
TBX2 is identified as a key transcription factor repressing vascular calcification by controlling RUNX2 and the inflammatory NLRP3 pathway, highlighting new therapeutic targets to reduce cardiovascular risk in CKD.
A large UK cohort study developed and externally validated a 100‑day prognostic model for allopurinol‑induced severe cutaneous adverse reactions (SCAR). Key predictors include age, CKD stage, high initial dose, and Asian ethnicity; discrimi
Large individual-patient meta-analyses show that 6-month albuminuria reduction and 3-year total GFR slope predict kidney failure across CKD populations—supporting their use as surrogate endpoints in randomized trials with caveats for chroni
The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type
CKD-associated pruritus affects up to 85% of dialysis patients and significantly impairs quality of life. Stepwise management, including novel therapies like nemolizumab, is essential for effective symptom control and improved patient outco
